Insider Trading March 3, 2026

Artivion Accounting Chief Sells Shares to Cover RSU Taxes as Stock Trades at Rich Multiple

Amy Horton disposed of 641 shares for $24,373; company posts better-than-expected Q4 2025 results amid valuation debate

By Marcus Reed AORT
Artivion Accounting Chief Sells Shares to Cover RSU Taxes as Stock Trades at Rich Multiple
AORT

Artivion VP and Chief Accounting Officer Amy Horton sold 641 shares on March 2, 2026, at $38.0249 per share for $24,373 to meet tax withholding obligations tied to vested restricted stock units. The move was non-discretionary. The medical device maker has seen a 53% stock gain over the past year but trades at a high P/E of 182.1 and is viewed as overvalued by InvestingPro. Artivion reported stronger-than-expected Q4 2025 results, with EPS of $0.17 and adjusted revenue of $118.3 million, while Canaccord Genuity trimmed its price target to $48 but left its Buy rating intact.

Key Points

  • Amy Horton, Artivion VP and Chief Accounting Officer, sold 641 shares on March 2, 2026, at $38.0249 per share for $24,373 to cover tax withholding on vested restricted stock units - the sale was non-discretionary.
  • Artivion's stock has risen about 53% over the past year and trades at a P/E ratio of 182.1; InvestingPro's Fair Value analysis indicates the company appears overvalued with a market cap of $1.84 billion.
  • Artivion exceeded Q4 2025 expectations with EPS of $0.17 and adjusted revenues of $118.3 million (an 18.5% constant-currency increase), prompting Canaccord Genuity to lower its price target to $48 from $51 while keeping a Buy rating.

Artivion NASDAQ:AORT disclosed a small insider sale by its vice president and chief accounting officer, Amy Horton. On March 2, 2026, Horton sold 641 shares of common stock at $38.0249 per share, producing gross proceeds of $24,373.

Following the transaction Horton continues to hold a substantial stake, directly owning 132,514 shares of Artivion. Company filings specify the disposal was executed to satisfy tax withholding obligations tied to the vesting of restricted stock units and was not a discretionary sale.


Market context for the transaction is notable. Artivion's share price has climbed roughly 53% over the last 12 months, and the stock currently trades at a price-to-earnings ratio of 182.1. According to InvestingPro, the company, which carries a market capitalization of $1.84 billion, appears overvalued at present based on its Fair Value analysis.


On the earnings front, Artivion reported fourth-quarter results for 2025 that outpaced expectations. The company posted earnings per share of $0.17, ahead of the consensus forecast of $0.06. Adjusted revenues reached $118.3 million, representing an 18.5% year-over-year increase on a constant currency basis. That revenue total excludes a one-time $2.3 million payment to the Italian government.

The reported revenue figure topped Canaccord Genuity's estimate of $115.6 million and the consensus estimate of $116.5 million. In reaction to recent market moves and compressed multiples across comparable groups, Canaccord Genuity reduced its price target for Artivion to $48 from $51, while maintaining a Buy rating.


Analysts and company commentary highlighted strong performance in key product areas and ongoing strategic growth initiatives as positive elements supporting the business. These developments were cited as part of Artivion's efforts to strengthen its financial position and market standing.

Investors parsing insider activity, valuation metrics and quarterly results will weigh the administrative nature of Horton's sale against the company's recent operational momentum and the differing views on valuation.

Risks

  • Valuation risk - The stock's high P/E of 182.1 and InvestingPro's assessment of overvaluation could weigh on investor returns and market sentiment in the healthcare and equity markets.
  • Market multiple compression - Canaccord Genuity cited compressed multiples across comparable groups amid a recent market sell-off, a factor that influenced its decision to reduce the price target; this presents uncertainty for the stock's near-term valuation.
  • One-time items and comparability - Adjusted revenue excludes a one-time $2.3 million payment to the Italian government, which can complicate year-over-year comparisons and make trend assessment more uncertain for healthcare investors and analysts.

More from Insider Trading

TransUnion International President Sells $38,320 in Stock as Company Posts Solid Quarter Mar 3, 2026 John B. Sanfilippo Insider Sells $583,954; Company Posts Strong Q2 Results Mar 3, 2026 Director Lisa Sanfilippo Disposes $185,008 of John B. Sanfilippo & Son Stock Mar 3, 2026 Waste Management CFO Executes Small Share Dispositions to Cover Tax and Settle Award Mar 3, 2026 RENN Fund President Murray Stahl Buys 1,134 Shares in RCG at $2.88 Mar 3, 2026